Skip to main content
Premium Trial:

Request an Annual Quote

GMSbiotech, PTS Partner to Develop Array-based Antibody Screening Solution

NEW YORK (GenomeWeb News) – GMSbiotech and Pure Transplant Solutions today announced a partnership to develop a new antibody screening solution.

The partnership leverages GMSbiotech's microarray-based diagnostic platform for personalized medicine and transplantation compatibility and PTS' HLA reagents, which include more than 200 Class I and II alleles. That number is anticipated to grow to more than 300 alleles during the course of the deal announced today, GMSbiotech and PTS said.

PTS CEO Thomas Harlan said that his firm has invested more than $15 million in the last 14 years to develop its PTS reagent technology, while GMSbiotech has invested more than $10 million during the past decade developing its platform.

"Leveraging our combined infrastructures and unique strengths will allow us to develop a novel technology solution while lowering the risk, time, and costs normally associated with these types of ventures," Harlan said in a statement.

Inverness, Ill.-based GMSbiotech develops genetic and serology tests based on its raw sample genotyping technology in combination with its microarray platform.

PTS is a subsidiary of Pure Protein based in Oklahoma City, Okla., and develops HLA protein technology methods and immunology tools for diagnostic and therapeutic applications.

Financial and other terms of the deal were not disclosed.